| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 654,473 | 743,294 | 659,836 | 525,110 |
| Restricted cash | 5,511 | 4,594 | 3,136 | 3,106 |
| Other receivables | 13,585 | 24,649 | 21,910 | 21,606 |
| Prepaid data assets | 11,742 | 11,742 | 0 | 0 |
| Other current assets | 24,246 | 28,566 | 29,223 | 37,338 |
| Total current assets | 709,557 | 812,845 | 714,105 | 587,160 |
| Restricted cash, non-current | 5,196 | 6,033 | 4,173 | 5,629 |
| Property and equipment, net | 95,811 | 103,931 | 111,706 | 120,038 |
| Operating lease right-of-use assets | 42,816 | 45,339 | 47,812 | 50,324 |
| Financing lease right-of-use assets | 18,694 | 20,210 | 21,726 | 23,242 |
| Intangible assets, net | 294,073 | 309,903 | 322,344 | 341,319 |
| Goodwill | 160,170 | 162,158 | 162,042 | 164,270 |
| Deferred tax assets | 957 | 957 | 957 | 957 |
| Other assets, non-current | 12,248 | 12,754 | 14,661 | 9,416 |
| Total assets | 1,339,522 | 1,474,130 | 1,399,526 | 1,302,355 |
| Accounts payable | 20,348 | 18,118 | 13,935 | 19,314 |
| Accrued expenses and other liabilities | 54,205 | 70,230 | 53,102 | 64,280 |
| Accrued data liability | NaN | NaN | 20,258 | 20,258 |
| Unearned revenue | 32,794 | 37,605 | 47,364 | 39,690 |
| Operating lease liabilities | 13,087 | 12,663 | 11,525 | 11,732 |
| Notes payable and financing lease liabilities | 9,265 | 9,091 | 8,919 | 8,752 |
| Total current liabilities | 129,699 | 147,707 | 155,103 | 164,026 |
| Unearned revenue, non-current | 114,723 | 114,012 | 111,204 | 126,243 |
| Operating lease liabilities, non-current | 42,842 | 46,647 | 50,028 | 53,395 |
| Notes payable and financing lease liabilities, non-current | 7,181 | 9,564 | 11,902 | 14,196 |
| Deferred tax liabilities | 18,283 | 23,255 | 23,312 | 23,784 |
| Other liabilities, non-current | 2,025 | 2,080 | 1,029 | 1,565 |
| Total liabilities | 314,753 | 343,265 | 352,578 | 383,209 |
| Common stock, 0.00001 par value 2,000,000,000 shares (class a 1,989,032,117 and class b 10,967,883) authorized as of march31, 2026 and december31, 2025 530,628,653 shares (class a 524,464,320, class b 5,307,334 and exchangeable 856,999) and 528,182,693 shares (class a 521,831,046, class b 5,547,334 and exchangeable 804,313) issued and outstanding as of march31, 2026 and december31, 2025, respectively | 5 | 5 | 5 | 4 |
| Additional paid-in capital | 3,191,608 | 3,170,145 | 2,980,729 | 2,681,111 |
| Accumulated deficit | -2,193,506 | -2,076,002 | -1,967,879 | -1,805,589 |
| Accumulated other comprehensive income (loss) | 26,662 | 36,717 | 34,093 | 43,620 |
| Total stockholders equity | 1,024,769 | 1,130,865 | 1,046,948 | 919,146 |
| Total liabilities and stockholders equity | 1,339,522 | 1,474,130 | 1,399,526 | 1,302,355 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)